{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:59:07Z","timestamp":1792803547731,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41375-023-01890-4","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T12:05:58Z","timestamp":1680782758000},"page":"1186-1190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["What role for somatic mutations in systemic inflammatory and autoimmune diseases associated with myelodysplastic neoplasms and chronic myelomonocytic leukemias?"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-4470","authenticated-orcid":false,"given":"Lin-Pierre","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"S\u00e9bert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2849-3049","authenticated-orcid":false,"given":"Ars\u00e8ne","family":"M\u00e9kinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5005-1664","authenticated-orcid":false,"given":"Marion","family":"Esp\u00e9li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0534-3198","authenticated-orcid":false,"given":"Karl","family":"Balabanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1243-6456","authenticated-orcid":false,"given":"Nicolas","family":"Dulphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"1890_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/rheumatology\/kev294","volume":"55","author":"A Mekinian","year":"2016","unstructured":"Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology. 2016;55:291\u2013300.","journal-title":"Rheumatology"},{"key":"1890_CR2","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","volume":"383","author":"DB Beck","year":"2020","unstructured":"Beck DB, Ferrada MA, Sikora KA, Ombrello AK, Collins JC, Pei W, et al. Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N. Engl J Med. 2020;383:2628\u201338.","journal-title":"N. Engl J Med"},{"key":"1890_CR3","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","volume":"3","author":"D McGonagle","year":"2006","unstructured":"McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;3:e297.","journal-title":"PLoS Med"},{"key":"1890_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2141.1986.tb07504.x","volume":"63","author":"GJ Mufti","year":"1986","unstructured":"Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol. 1986;63:143\u20137.","journal-title":"Br J Haematol"},{"key":"1890_CR5","doi-asserted-by":"publisher","first-page":"E280","DOI":"10.1002\/ajh.24333","volume":"91","author":"RS Komrokji","year":"2016","unstructured":"Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016;91:E280\u20133.","journal-title":"Am J Hematol"},{"key":"1890_CR6","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1038\/s41375-021-01353-8","volume":"35","author":"L-P Zhao","year":"2021","unstructured":"Zhao L-P, Schell B, S\u00e9bert M, Kim R, Lemaire P, Boy M, et al. Prevalence of UBA1 mutations in MDS\/CMML patients with systemic inflammatory and auto-immune disease. Leukemia. 2021;35:2731\u20133.","journal-title":"Leukemia"},{"key":"1890_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjd.20805","volume":"186","author":"S Georgin-Lavialle","year":"2022","unstructured":"Georgin-Lavialle S, Terrier B, Guedon AF, Heiblig M, Comont T, Lazaro E, et al. Further characterization of clinical and laboratory features occurring in VEXAS syndrome in a large-scale analysis of multicenter case-series of 116 French patients. Br J Dermatol. 2022;186:564\u201374.","journal-title":"Br J Dermatol"},{"key":"1890_CR8","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1093\/rheumatology\/keab392","volume":"60","author":"T Barba","year":"2021","unstructured":"Barba T, Jamilloux Y, Durel C-A, Bourbon E, Mestrallet F, Sujobert P, et al. VEXAS syndrome in a woman. Rheumatology. 2021;60:e402\u20133.","journal-title":"Rheumatology"},{"key":"1890_CR9","doi-asserted-by":"publisher","first-page":"e775","DOI":"10.1097\/HS9.0000000000000775","volume":"6","author":"C Gurnari","year":"2022","unstructured":"Gurnari C, Mannion P, Pandit I, Pagliuca S, Voso MT, Maciejewski JP, et al. UBA1 Screening in Sweet Syndrome With Hematological Neoplasms Reveals a Novel Association Between VEXAS and Chronic Myelomonocytic. Leuk Hemasphere. 2022;6:e775.","journal-title":"Leuk Hemasphere"},{"key":"1890_CR10","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.3324\/haematol.2021.279418","volume":"106","author":"M Hage-Sleiman","year":"2021","unstructured":"Hage-Sleiman M, Lalev\u00e9e S, Guermouche H, Favale F, Chaquin M, Battistella M, et al. Dominance of an UBA1 mutant clone over a CALR mutant clone: from essential thrombocytemia to VEXAS. Haematologica. 2021;106:3245\u20138.","journal-title":"Haematologica"},{"key":"1890_CR11","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood.2022016985","volume":"140","author":"MA Ferrada","year":"2022","unstructured":"Ferrada MA, Savic S, Cardona DO, Collins JC, Alessi H, Gutierrez-Rodrigues F, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022;140:1496\u2013506.","journal-title":"Blood"},{"key":"1890_CR12","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1182\/blood.2022016835","volume":"14","author":"F Caiado","year":"2023","unstructured":"Caiado F, Kovtonyuk LV, Gonullu NG, Fullin J, Boettcher S, Manz MG. Aging drives Tet2+\/- clonal hematopoiesis via IL-1 signaling. Blood. 2023;14:886\u2013903.","journal-title":"Blood"},{"key":"1890_CR13","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1158\/2159-8290.CD-22-0086","volume":"12","author":"JM SanMiguel","year":"2022","unstructured":"SanMiguel JM, Eudy E, Loberg MA, Young KA, Mistry JJ, Mujica KD, et al. Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 2022;12:2763\u201373.","journal-title":"Cancer Discov"},{"key":"1890_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1126\/science.aba9304","volume":"374","author":"S Avagyan","year":"2021","unstructured":"Avagyan S, Henninger JE, Mannherz WP, Mistry M, Yoon J, Yang S, et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science. 2021;374:768\u201372.","journal-title":"Science"},{"key":"1890_CR15","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","volume":"100","author":"LA Anderson","year":"2009","unstructured":"Anderson LA, Pfeiffer RM, Landgren O, Gadalla S, Berndt SI, Engels EA. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer. 2009;100:822\u20138.","journal-title":"Br J Cancer"},{"key":"1890_CR16","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1038\/s41375-021-01152-1","volume":"35","author":"L-P Zhao","year":"2021","unstructured":"Zhao L-P, Boy M, Azoulay C, Clappier E, S\u00e9bert M, Amable L, et al. Genomic landscape of MDS\/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 2021;35:2720\u20134.","journal-title":"Leukemia"},{"key":"1890_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2141.2009.07593.x","volume":"145","author":"SY Kordasti","year":"2009","unstructured":"Kordasti SY, Afzali B, Lim Z, Ingram W, Hayden J, Barber L, et al. IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol. 2009;145:64\u201372.","journal-title":"Br J Haematol"},{"key":"1890_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/sj.leu.2404590","volume":"21","author":"PK Epling-Burnette","year":"2007","unstructured":"Epling-Burnette PK, Painter JS, Rollison DE, Ku E, Vendron D, Widen R, et al. Prevalence and clinical association of clonal T-cell expansions in Myelodysplastic Syndrome. Leukemia. 2007;21:659\u201367.","journal-title":"Leukemia"},{"key":"1890_CR19","doi-asserted-by":"crossref","unstructured":"Wesner N, Drevon L, Guedon A, Fraison JB, Terrier B, Trad S, et al. Gastrointestinal Behcet\u2019s-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review. Leuk Lymphoma 2019;7:1782\u20138.","DOI":"10.1080\/10428194.2018.1542152"},{"key":"1890_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3904\/kjim.2018.247","volume":"35","author":"Y-J Oh","year":"2020","unstructured":"Oh Y-J, Shin D-Y, Hwang SM, Kim S-M, Im K, Park HS, et al. Mutation of ten-eleven translocation-2 is associated with increased risk of autoimmune disease in patients with myelodysplastic syndrome. Korean J Intern Med. 2020;35:457\u201364.","journal-title":"Korean J Intern Med"},{"key":"1890_CR21","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1182\/blood.2020010163","volume":"138","author":"JS Hecker","year":"2021","unstructured":"Hecker JS, Hartmann L, Rivi\u00e8re J, Buck MC, van der Garde M, Rothenberg-Thurley M, et al. CHIP and hips: clonal hematopoiesis is common in patients undergoing hip arthroplasty and is associated with autoimmune disease. Blood. 2021;138:1727\u201332.","journal-title":"Blood"},{"key":"1890_CR22","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood.2021011320","volume":"138","author":"M Rossi","year":"2021","unstructured":"Rossi M, Meggendorfer M, Zampini M, Tettamanti M, Riva E, Travaglino E, et al. Clinical relevance of clonal hematopoiesis in persons aged \u226580 years. Blood 2021;138:2093\u2013105.","journal-title":"Blood"},{"key":"1890_CR23","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1182\/blood-2021-152302","volume":"138","author":"D Elessa","year":"2021","unstructured":"Elessa D, Zhao L-P, Daltro De Oliveira R, Maslah N, Soret-Dulphy J, Verger E, et al. Genomic landscape and clinical features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID). Blood. 2021;138:1496.","journal-title":"Blood"},{"key":"1890_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ccr.2011.06.003","volume":"20","author":"C Quivoron","year":"2011","unstructured":"Quivoron C, Couronn\u00e9 L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human Lymphomagenesis. Cancer Cell. 2011;20:25\u201338.","journal-title":"Cancer Cell"},{"key":"1890_CR25","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/s41375-018-0047-7","volume":"32","author":"CM Arends","year":"2018","unstructured":"Arends CM, Galan-Sousa J, Hoyer K, Chan W, J\u00e4ger M, Yoshida K, et al. Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. Leukemia. 2018;32:1908\u201319.","journal-title":"Leukemia"},{"key":"1890_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","volume":"355","author":"JJ Fuster","year":"2017","unstructured":"Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355:842\u20137.","journal-title":"Science"},{"key":"1890_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood.2022015384","volume":"140","author":"M Agrawal","year":"2022","unstructured":"Agrawal M, Niroula A, Cunin P, McConkey M, Shkolnik V, Kim PG, et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood. 2022;140:1094\u2013103.","journal-title":"Blood"},{"key":"1890_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1182\/blood.2021013531","volume":"139","author":"PG Miller","year":"2022","unstructured":"Miller PG, Qiao D, Rojas-Quintero J, Honigberg MC, Sperling AS, Gibson CJ, et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood. 2022;139:357\u201368.","journal-title":"Blood"},{"key":"1890_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","volume":"377","author":"S Jaiswal","year":"2017","unstructured":"Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl J Med. 2017;377:111\u201321.","journal-title":"N. Engl J Med"},{"key":"1890_CR30","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1084\/jem.20151438","volume":"213","author":"X Yue","year":"2016","unstructured":"Yue X, Trifari S, \u00c4ij\u00f6 T, Tsagaratou A, Pastor WA, Zepeda-Mart\u00ednez JA, et al. Control of Foxp3 stability through modulation of TET activity. J Exp Med. 2016;213:377\u201397.","journal-title":"J Exp Med"},{"key":"1890_CR31","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1158\/2159-8290.CD-18-0657","volume":"8","author":"PM Dominguez","year":"2018","unstructured":"Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, B\u00e9guelin W, Font\u00e1n L, et al. TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell Lymphomagenesis. Cancer Disco. 2018;8:1632\u201353.","journal-title":"Cancer Disco"},{"key":"1890_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36193-w","volume":"14","author":"M Boy","year":"2023","unstructured":"Boy M, Bisio V, Zhao L-P, Guidez F, Schell B, Lereclus E, et al. Myelodysplastic Syndrome associated TET2 mutations affect NK cell function and genome methylation. Nat Commun. 2023;14:588.","journal-title":"Nat Commun"},{"key":"1890_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","volume":"34","author":"MS Waitkus","year":"2018","unstructured":"Waitkus MS, Diplas BH, Yan H. Biological role and therapeutic potential of IDH mutations in cancer. Cancer Cell. 2018;34:186\u201395.","journal-title":"Cancer Cell"},{"key":"1890_CR34","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/nm.4097","volume":"22","author":"SC-W Lee","year":"2016","unstructured":"Lee SC-W, Dvinge H, Kim E, Cho H, Micol J-B, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22:672\u20138.","journal-title":"Nat Med"},{"key":"1890_CR35","doi-asserted-by":"publisher","unstructured":"Kosmider O, Poss\u00e9m\u00e9 C, Templ\u00e9 M, Corneau A, Carbone F, Duroyon E, et al. VEXAS syndrome is characterized by blood and tissues inflammasome pathway activation and monocyte dysregulation. medRxiv 2022; https:\/\/doi.org\/10.1101\/2022.10.12.22281005.","DOI":"10.1101\/2022.10.12.22281005"},{"key":"1890_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.leukres.2016.02.005","volume":"43","author":"J-B Fraison","year":"2016","unstructured":"Fraison J-B, Mekinian A, Grignano E, Kahn J-E, Arlet J-B, Decaux O, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016;43:13\u201317.","journal-title":"Leuk Res"},{"key":"1890_CR37","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","volume":"36","author":"A Mekinian","year":"2022","unstructured":"Mekinian A, Zhao LP, Chevret S, Desseaux K, Pascal L, Comont T, et al. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML. Leukemia. 2022;36:2739\u201342.","journal-title":"Leukemia"},{"key":"1890_CR38","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1007\/s11899-015-0284-z","volume":"10","author":"DP McLornan","year":"2015","unstructured":"McLornan DP, Khan AA, Harrison CN. Immunological consequences of JAK inhibition: friend or foe? Curr Hematol Malig Rep. 2015;10:370\u20139.","journal-title":"Curr Hematol Malig Rep"},{"key":"1890_CR39","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398:803\u201316.","journal-title":"Lancet"},{"key":"1890_CR40","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1182\/bloodadvances.2021004749","volume":"6","author":"A Diarra","year":"2022","unstructured":"Diarra A, Duployez N, Fournier E, Preudhomme C, Coiteux V, Magro L, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a two-center experience. Blood Adv. 2022;6:998\u20131003.","journal-title":"Blood Adv"},{"key":"1890_CR41","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.18488","volume":"199","author":"A Al-Hakim","year":"2022","unstructured":"Al-Hakim A, Poulter JA, Mahmoud D, Rose AMS, Elcombe S, Lachmann H, et al. Allogeneic haematopoietic stem cell transplantation for VEXAS syndrome: UK experience. Br J Haematol. 2022;199:777\u201381.","journal-title":"Br J Haematol"},{"key":"1890_CR42","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/leu.2011.71","volume":"25","author":"R Itzykson","year":"2011","unstructured":"Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25:1147\u201352.","journal-title":"Leukemia"},{"key":"1890_CR43","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/17474086.2017.1346470","volume":"10","author":"KE Lindblad","year":"2017","unstructured":"Lindblad KE, Goswami M, Hourigan CS, Oetjen KA. Immunological effects of hypomethylating agents. Expert Rev Hematol. 2017;10:745\u201352.","journal-title":"Expert Rev Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01890-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01890-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T20:29:22Z","timestamp":1686083362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-01890-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1890"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-01890-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}